Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

M&A Activity in 2012 Will Surpass Last Year’s Pace, GEN Online Readers Predict

  • A more than 3-to-1 majority of GEN online readers believe that M&A activity among drug developers in 2012 will surpass that of 2011. Voting 70.7% to 20.7%, with 8.6% undecided, respondents offered a sunny forecast for mergers and acquisitions among biopharmaceutical companies. While M&A activity was strong in 2011, the number of those huge blockbuster agreements seemed to be lower. Sanofi topped last year’s list of biggest M&A deals with its $20.1 billion buy of Genzyme—about half of the $41 billion that 2010’s top-spender, Novartis, paid for Alcon. The top-five list for 2011 ended with Forest Laboratories’ $1.2 billion purchase of Clinical Data, while last year the fifth place went to Daiichi Sankyo when it bought Ranbaxy for $4.6 billion.

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »